Compare UNB & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UNB | TLSA |
|---|---|---|
| Founded | 1891 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.6M | 145.1M |
| IPO Year | 1999 | 2017 |
| Metric | UNB | TLSA |
|---|---|---|
| Price | $22.96 | $0.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.11 |
| AVG Volume (30 Days) | 4.1K | ★ 605.9K |
| Earning Date | 10-21-2026 | 05-01-2026 |
| Dividend Yield | ★ 6.38% | N/A |
| EPS Growth | ★ 25.52 | N/A |
| EPS | ★ 1.25 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.65 | $0.62 |
| 52 Week High | $26.41 | $1.90 |
| Indicator | UNB | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 38.88 | 29.82 |
| Support Level | N/A | N/A |
| Resistance Level | $24.16 | $1.21 |
| Average True Range (ATR) | 0.40 | 0.08 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 10.26 | 16.20 |
Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The Company has one definable business segment, Union Bank, which provides full retail, commercial, municipal banking, and wealth management and trust services throughout its 18 branch banking locations, three loan centers, and several ATMs covering northern Vermont and northern New Hampshire. In addition, it also offers fiduciary and asset management services through its Asset Management Group.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.